Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Seminars in diagnostic pathology

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.semdp.2015.02.011PMID 25770732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

  2014cited by this paper
• Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

  2014cited by this paper
• In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

  2014cited by this paper
• Low ER+ breast cancer: Is this a distinct group?

  2014cited by this paper
• Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

  2013cited by this paper
• Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.

  2013cited by this paper
• SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases

  2013cited by this paper
• Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

  2013cited by this paper
• Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?

  2013cited by this paper
• Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.

  2013cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

  2013cited by this paper
• Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

  2013cited by this paper
• Treating the HER2 pathway in early and advanced breast cancer.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis

  2012cited by this paper
• Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study

  2012cited by this paper
• Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

  2012cited by this paper
• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

  2012cited by this paper
• Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.

  2012cited by this paper
• A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

  2012cited by this paper
• Practical implications of gene-expression-based assays for breast oncologists

  2012cited by this paper
• Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

  2011cited by this paper
• Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.

  2011cited by this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

  2011cited by this paper
• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

  2011cited by this paper
• High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

  2011cited by this paper
• Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

  2011cited by this paper
• Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

  2011cited by this paper
• OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007.

  2011cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Fixation time does not affect expression of HER2/neu: a pilot study.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

  2010cited by this paper
• Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

  2010cited by this paper
• Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis

  2009cited by this paper
• Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

  2009cited by this paper
• Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

  2009cited by this paper
• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  2008cited by this paper
• Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

  2008cited by this paper
• Problems and solutions in the evaluation of hormone receptors in breast cancer.

  2008cited by this paper
• Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

  2008cited by this paper
• The MINDACT trial: The first prospective clinical validation of a genomic tool

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• TAILORx: trial assigning individualized options for treatment (Rx).

  2006cited by this paper
• Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

  2006cited by this paper
• Estrogen receptor testing of breast cancer in current clinical practice: what's the question?

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

  2005cited by this paper
• Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases.

  2005cited by this paper
• HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

  2004cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

  1999cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

  1985cited by this paper

• Nebivolol attenuates acute systemic inflammation induced testicular dysfunction by decreasing transendothelial migration via VCAM-1/MMP-9 signaling

  2025cites this paper
• Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes

  2025cites this paper
• Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

  2025cites this paper
• A prediction model for predicting relapsed-free survival of early-stage invasive breast cancer patients with hormone receptor positive based on Ki67, HER2 and TOP2A

  2025cites this paper
• Network pharmacology analysis revealed novel target genes of Astragaloside IV in breast cancer and breast cancer stem cells

  2025cites this paper
• Landscape of lncRNAs expressed in Mexican patients with triple‑negative breast cancer

  2025cites this paper
• An overview about biomarkers in breast cancer: Insights into the diagnostic and prognostic significance.

  2024cites this paper
• Occult breast cancer in an older woman: A case report

  2024cites this paper
• Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer

  2024cites this paper
• Identifying the effectiveness of 3D culture systems to recapitulate breast tumor tissue in situ

  2023cites this paper
• Potential Hepatoprotective Effects of Irbesartan, an Accessible Angiotensin II Receptor Blocker, Against Cisplatin-Induced Liver Injury in a Rat Model

  2023cites this paper
• Association Between Contrast‐Enhanced Ultrasound Characteristics and Molecular Subtypes of Breast Cancer

  2021cites this paper
• Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach

  2021cites this paper
• Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

  2021cites this paper
• Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

  2021cites this paper
• Immunohistochemical expression of HER-2 and Ki-67 in granulosa cell tumor in bitches.

  2021cites this paper
• Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

  2020cites this paper
• Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer

  2020cites this paper
• Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

  2020cites this paper
• Characterizing the Relapse Potential in Different Luminal Subtypes of Breast Cancers with Functional Proteomics

  2020cites this paper
• Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma

  2020cites this paper
• CMAR_A_237423 2491..2499

  2020cites this paper
• High-Grade Transformation of Low-Grade Endometrial Stromal Sarcomas Lacking YWHAE and BCOR Genetic Abnormalities

  2020cites this paper
• HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

  2020cites this paper
• The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

  2020cites this paper
• Breast Pathology

  2020cites this paper
• Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients

  2019cites this paper
• Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

  2019cites this paper
• Breast cancer genetic susceptibility: With focus in Saudi Arabia

  2019cites this paper
• Hunting a Silent Killer. Biomolecular Approaches in Ovarian Cancer

  2019cites this paper
• The estrogen effect; clinical and histopathological evidence of dichotomous influences in dogs with spontaneous mammary carcinomas

  2019cites this paper
• OTT_A_221335 8789..8800

  2019cites this paper
• Efficacité et tolérance du paclitaxel hebdomadaire dans le cancer du sein avec envahissement médullaire symptomatique

  2019cites this paper
• Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients

  2019cites this paper
• long noncoding rna h19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and eMT process

  2018cites this paper
• HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy

  2018cites this paper
• long noncoding rna h19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and eMT process

  2018cites this paper
• Blood-derived non-extracellular vesicle proteins as potential biomarkers for the diagnosis of early ER+ breast cancer and detection of lymph node involvement

  2018cites this paper
• HER2-targeted therapy: an emerging strategy in advanced colorectal cancer

  2018cites this paper
• Comparative oncology research in Australia: establishing the Australian Veterinary Cancer Biobank to validate canine mammary tumours as a model for human breast cancer

  2018cites this paper
• Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process

  2018cites this paper
• Moesin is an independent prognostic marker for ER-positive breast cancer.

  2018cites this paper
• The Assessment of HER2 Gene Status by Fluorescence In Situ Hybridization in Invasive Breast Carcinomas With Equivocal HER2 Immunostaining: Experience From a Single Institution

  2018cites this paper
• Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data.

  2017cites this paper
• Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.

  2017cites this paper
• Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

  2017cites this paper
• Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors

  2017influential citation
• Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

  2017cites this paper
• Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy

  2017cites this paper
• Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

  2017cites this paper
• Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T

  2017cites this paper
• An optimized image analysis algorithm for detecting nuclear signals in digital whole slides for histopathology

  2017cites this paper
• Association of three single nucleotide polymorphisms of ESR1 with breast cancer susceptibility: a meta-analysis

  2017cites this paper
• Improving accuracy of breast cancer biomarker testing in India

  2017cites this paper
• Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y

  2016cites this paper
• Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms

  2016cites this paper
• Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative

  2016cites this paper
• Tumor Phenotype and Gene Expression During Early Mammary Tumor Development in Offspring Exposed to Alcohol In Utero.

  2016cites this paper
• Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women

  2016cites this paper
• Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China.

  2015cites this paper
• Translational progress on tumor biomarkers

  2015cites this paper
• Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience

  2015cites this paper